Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myeloma
•
Hematology
How do you evaluate a patient with MGUS and peripheral neuropathy?
Can you explain when would you consider light chain amyloidosis work up with fat pad biopsy?
Related Questions
How do you utilize immunoglobulin testing to affect treatment decisions in patients with myeloma?
How is monoclonal gammopathy of renal significance (MGRS) different from myeloma kidney?
How do you monitor multiple myeloma in patients receiving dialysis?
Does the presence of osteoporosis change the extent of workup that should be performed for an older patient with otherwise serologically low-risk MGUS?
What induction regimen do you choose for high risk newly diagnosed multiple myeloma in light of the recent high risk focused studies?
How do you discuss harms of MGUS screening with other medical providers?
For otherwise transplant-eligible patients with myeloma, given developments of bispecifics and CAR-T, what is your age cutoff for consolidative autologous transplant?
How does one approach maintenance treatment in transplant in-eligible patients with newly diagnosed multiple myeloma?
With the recent approvals of CAR-T for second-line therapy in myeloma, does this change your approach to use of consolidative autologous transplant or autologous transplant as second line therapy?
What is your approach to vaccinations and titers for patients with myeloma, who are immunosuppressed and do not have appropriate antibody responses to vaccines?